Log in to search using one of your social media accounts:

 

Amantadine ER Curbs Levodopa-Induced Dyskinesia in PDAmantadine ER Curbs Levodopa-Induced Dyskinesia in PD

An investigational extended-release formulation of amantadine with a unique chronotherapeutic pharmacokinetic profile eases levodopa-induced dyskinesia in a phase 2/3 study. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Conclusions This cohort describing the clinical characteristics of 69 patients is the largest cohort studied for THP addiction. Patients from the Centres for Addiction Prevention and Treatment were the youngest and most recently addicted, whereas general practice patients had been addicted for longer and were more socially integrated. This clinical description of THP addiction therefore enables us to identify the patients who are the most at risk, to set up an adapted care protocol.
Source: Journal of Clinical Psychopharmacology - Category: Psychiatry Tags: Brief Reports Source Type: research
Conclusions: The present results suggest that lamotrigine rechallenge may be a viable option for treatment-resistant bipolar disorder. PMID: 29659202 [PubMed - in process]
Source: The Primary Care Companion for CNS Disorders - Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
CONCLUSIONS: We are uncertain about the evidence of the effects of baclofen, progabide, sodium valproate or tetrahydroisoxazolopyridinol (THIP) for people with antipsychotic-induced TD. Evidence is inconclusive and unconvincing. The quality of data available for main outcomes ranges from very low to low. Any possible benefits are likely to be outweighed by the adverse effects associated with their use. PMID: 29663328 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Conclusions This trial will evaluate clinical effects of acupuncture in PD patients, and will confirm whether acupuncture alters neurotransmitter levels and associated activities. We expect improvement in gait parameters, changes in motor and prefrontal cortex activity, and changes in neurotransmitter activity, thereby providing insight into the therapeutic mechanism of acupuncture in PD and supporting further studies of whether acupuncture may improve motor symptoms in PD.
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Publication date: March 2018 Source:Neurochemistry International, Volume 114 Author(s): Corinne Y. Ostock, Nirmal Bhide, Adam A. Goldenberg, Jessica A. George, Christopher Bishop l-DOPA remains the primary treatment for Parkinson's disease (PD). Unfortunately, its therapeutic benefits are compromised by the development of abnormal involuntary movements (AIMs) known as l-DOPA-induced dyskinesia (LID). The norepinephrine (NE) system originating in the locus coeruleus is profoundly affected in PD and known to influence dopamine (DA) signaling. However, the effect of noradrenergic loss on l-DOPA-induced striatal monoamine eff...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
Condition:   Tardive Dyskinesia Interventions:   Device: Active tDCS;   Device: Sham tDCS Sponsor:   Suzhou Psychiatric Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractPrimary ciliary dyskinesia (PCD) restricts lifestyle and increases morbidity. The aim of the study was to investigate anaerobic and aerobic performance in children with PCD and their healthy counterparts. Thirty-one children with PCD and 29 age- and sex-matched healthy subjects were studied. Pulmonary function, hand grip strength (HGS), quadriceps strength (QMS), physical activity, anaerobic capacity (muscle power sprint test), and aerobic performance (modified shuttle walk test (MSWT)) were determined. Pulmonary function, HGS, QMS, mean anaerobic power (MAP), and MSWT distance in PCD were significantly lower than ...
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research
Conditions:   Schizophrenia;   Schizoaffective Disorder;   Tobacco Smoking;   Tardive Dyskinesia;   Parkinsonism Intervention:   Drug: Varenicline Sponsor:   Corporal Michael J. Crescenz VA Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Cystic Fibrosis;   Primary Ciliary Dyskinesia Intervention:   Other: Analysis with sequencing of the genotype of the bacteria Sponsor:   Centre Hospitalier Intercommunal Creteil Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Schizophrenia;   Schizoaffective Disorder;   Tobacco Smoking;   Tardive Dyskinesia;   Parkinsonism Intervention:   Drug: Varenicline Sponsor:   Corporal Michael J. Crescenz VA Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Amantadine | Brain | Carbidopa/Levodopa | Dyskinesia | Health | Neurology | Neurosurgery | Study | Symmetrel